Exousia Bio, Inc. (LMMY)
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
Sector: Services-Educational Services
Industry: Education & Training Services
L A M Y
OTC:LMMYConsumer Defensive · Education & Training Services
-15.38%$0.0121
Mkt Cap$635K
Float47.48M
O/S52.5M
Inst Own-
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$4K
Net Income$51K
Total Assets$0
Free Cash Flow-$5K
Debt & Equity
Debt 2590%
Total Debt$57K
Total Equity-$55K
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in LMMY's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$27K
Liabilities$82K
Accounts Receivable$12K
Accounts Payable$0
Inventory$0
PP&E (Net)$5K
Goodwill$0
Intangible Assets$10K
Income Statement
| Period | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-05-31 | 2024-05-31 | 2023-05-31 |
| Revenue | $4K | $12K | $0 |
| YoY Growth | -67.4% | - | - |
| Cost of Revenue | $7K | $10K | $0 |
| Gross Profit | -$4K | $2K | $0 |
| Gross Margin | -93.4% | 15.9% | - |
| Research and Development | $0 | $0 | $0 |
| Selling, General, and Administrative | $28K | $28K | $56K |
| Other | $0 | $0 | $0 |
| Total Operating Expenses | $28K | $28K | $56K |
| Operating Income (EBIT) | -$32K | -$26K | -$56K |
| Operating Margin | -850.2% | -228.2% | - |
| Interest Expense | $0 | $0 | $0 |
| Interest Income | $0 | $0 | $0 |
| Other Income (Expense) | $83K | $436 | -$56K |
| Income Before Tax (EBT) | $51K | -$26K | -$56K |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $51K | -$26K | -$56K |
| Net Income Margin | 1370.5% | -224.4% | - |
| Supplementary Data | |||
| EPS | 0.01 | -0.00 | -0.01 |
| Diluted EPS | 0.01 | -0.00 | -0.01 |
| Weighted Average OS | 7.78M | 7.78M | 7.78M |
| EBITDA | $55K | -$12K | -$42K |
| EBITDA Margin | 1471.2% | -100.4% | - |
Balance Sheet
| Period | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-05-31 | 2024-05-31 | 2023-05-31 |
| Assets | |||
| Current Assets | |||
| Cash and Cash Equivalents | $0 | $1K | $8K |
| Short-Term Investments | $0 | $0 | $0 |
| Cash and Short-Term Investments | $0 | $1K | $8K |
| Accounts Receivable | $0 | $12K | $0 |
| Inventory | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 |
| Total Current Assets | $0 | $13K | $8K |
| Long-Term Assets | |||
| Property, Plant & Equipment Net | $0 | $5K | $10K |
| Goodwill | $0 | $0 | $0 |
| Intangible Assets | $0 | $10K | $0 |
| Long-Term Investments | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 |
| Total Long-Term Assets | $0 | $14K | $29K |
| Other Assets | $0 | $0 | $0 |
| Total Assets | $0 | $27K | $37K |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 |
| Total Current Liabilities | $0 | $14K | $4K |
| Long-Term Liabilities | |||
| Long-Term Debt | $0 | $57K | $57K |
| Long-Term Unearned Revenue | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $11K | $5K |
| Total Long-Term Liabilities | $0 | $68K | $63K |
| Other Liabilities | $0 | $0 | $0 |
| Total Liabilities | $0 | $82K | $66K |
| Stockholders' Equity | |||
| Preferred Stock | $0 | $0 | $0 |
| Common Stock | $778 | $778 | $778 |
| Retained Earnings | -$32K | -$83K | -$57K |
| Comprehensive Income & Other | $0 | $0 | $0 |
| Other Stockholders' Equity | - | $27K | $27K |
| Total Equity | $0 | -$55K | -$29K |
| Minority Interest | $0 | $0 | $0 |
| Total Liabilities and Equity | $0 | $27K | $37K |
| Supplementary Data | |||
| Total Debt | $0 | $57K | $57K |
| Net Debt | $0 | $56K | $49K |
Cash Flow Statement
| Period | FY 2024 | FY 2022 |
|---|---|---|
| Currency | USD | USD |
| Period Ending | 2025-05-31 | 2023-05-31 |
| Operating Activities | ||
| Net Income | $51K | -$56K |
| Depreciation & Amortization | $4K | $15K |
| Deferred Income Tax | $0 | $0 |
| Stock-Based Compensation | $0 | $0 |
| Changes in Working Capital: | ||
| Accounts Receivable | $12K | $0 |
| Inventory | $0 | $0 |
| Accounts Payable | $0 | $0 |
| Other Working Capital | $0 | $4K |
| Total Working Capital Change | $0 | $4K |
| Other Non-Cash Items | -$60K | $0 |
| Net Cash from Operating | -$5K | -$38K |
| Investing Activities | ||
| Capital Expenditures | $0 | $0 |
| Acquisitions | $0 | $0 |
| Purchases of Investments | $0 | $0 |
| Sales of Investments | $0 | $0 |
| Other Investing Activities | $0 | $0 |
| Net Cash from Investing | $0 | $0 |
| Financing Activities | ||
| Debt Repaid | - | -$3K |
| Common Stock Issuance | $0 | $28K |
| Common Stock Repurchases | $0 | $0 |
| Dividends Paid | $0 | $0 |
| Other Financing Activities | $4K | $5K |
| Net Cash from Financing | $4K | $36K |
| Forex Effect | $0 | $0 |
| Net Change in Cash | -$1K | -$2K |
| Supplementary Data | ||
| Operating Cash Flow | -$5K | -$38K |
| Capital Expenditure | $0 | $0 |
| Free Cash Flow | -$5K | -$38K |
| Cash at Beginning | $1K | $10K |
| Cash at End | $0 | $8K |